Olink Bioscience this week appointed Simon Fredriksson as its new president and CEO, replacing Bjorn Ekstrom, who has led the company since its founding in 2004 and will be joining its board of directors.
In addition to Ekstrom, Olle Kampe and Hakan Englund have joined the board of directors. The company also appointed Bengt Ågerup as chairman.
Ågerup has held senior positions within Pharmacia Biotech (now GE Healthcare) and Biomatrix, and he started the company Q-Med, which was subsequently sold to Galderma in 2011. He also is the founder of investment firm Nxt2b, which this month purchased 49 percent of Olink's outstanding shares (PM 09/02/2011).
Kampe is a professor of molecular medicine at Uppsala University and a scientific adviser to Nxt2b.
Englund is a board member of Uppsala Bio and the Uppsala Chamber of Commerce and previously held positions at Phadia and Pharmacia Biotech.
Fredriksson was previously Olink's executive vice president and chief scientific officer.
Bruker said this week that William Knight will remain as the firm's chief financial officer permanently.
Knight took over the role on an interim basis in June when former CFO Brian Monahan stepped down. Knight will also remain as interim chief operating officer while the company continues its search for senior operation executives for the areas of manufacturing engineering, production, logistics, and global supply chain management.
Roche this week named Rainer Metternich as its head of small molecule research, replacing Klaus Strein, who is retiring.
Prior to joining Roche, Metternich was chief scientific officer and chief business officer for proteomics firm Caprotec. Before that he worked for pharma companies including Novartis, Schering, and Merck.
Teri List-Stoll has been appointed to Danaher's board of directors.
List-Stoll has served as SVP and treasurer of Procter & Gamble since 2009. Prior to joining P&G in 1994, she was affiliated with accounting firm Deloitte & Touche. Her term as a member of Danaher's board expires at the firm's 2012 annual meeting of shareholders.
Shimadzu UK has appointed Robert Keighley as its new spectroscopy and TOC business manager.
Between 2000 and 2010 Keighley was employed by Varian and then Agilent, which acquired Varian last year, as product specialist for the Cary series of UV-Vis and NIR/FTIR products. From 1988 to 2000 he worked for Beckman Coulter in a number of roles including product manager for analytical centrifugation and product specialist for DNA sequencers, said Shimadzu.